Liezl Gambe

Kaos Capital, an activist hedge fund based in Miami, has acquired a 4.9% stake in BioRestorative Therapies (NASDAQ:BRTX) and plans to push the biotechnology company to pivot toward artificial intelligence opportunities.

Bath & Body Works (NYSE:BBWI) reported a 3% decline in net sales for the first quarter of 2026, reflecting a broader normalization of consumer spending within the beauty and home fragrance categories.

Capri Holdings (NYSE:CPRI) reported a 3.7% decline in fourth-quarter revenue for fiscal 2026, as the luxury fashion group continued to navigate broader demand headwinds across the global consumer discretionary sector.

Kingsoft Cloud Holdings (NASDAQ:KC) reported a 37.2% year-over-year surge in total revenue for the first quarter of 2026, driven by expanding artificial intelligence demand and deeper penetration into enterprise accounts.

Gilead Sciences (NASDAQ:GILD) released new results from a post hoc analysis of its open-label Phase 3 ASSURE study, demonstrating that its approved drug Livdelzi (seladelpar) achieved high and sustained rates of normalization in a key biomarker of liver disease progression.

AustralianSuper, the nation’s largest superannuation fund, appointed long-serving insider Shaun Manuell as its next chief investment officer.

Lithium Energy (ASX:LEL) announced a substantial new graphite exploration target in Queensland.

Cauldron Energy (ASX:CXU) has bolstered its uranium prospects at the Yanrey Project.

Straker (ASX:STG) issued a market update regarding an ongoing investigation into transaction anomalies within its United States subsidiary, Straker Translations.

Cosmos Exploration (ASX:C1X) finalised its merger with EAU Lithium after receiving shareholder approval.